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Background: Non-invasive ventilation (NIV) tolerance is a key factor of NIV success. Hence, numerous sedative
pharmacological or non-pharmacological strategies have been assessed to improve NIV tolerance. Music therapy in
various health care settings has shown beneficial effects. In invasively ventilated critical care patients, encouraging
results of music therapy on physiological parameters, anxiety, and agitation have been reported. We hypothesize
that a musical intervention improves NIV tolerance in comparison to conventional care. We therefore question the
potential benefit of a receptive music session administered to patients by trained caregivers (“musical intervention”)
to enhance acceptance and tolerance of NIV.
Methods/design: We conduct a prospective, three-center, open-label, three-arm randomized trial involving
patients in the intensive care unit (ICU) who require NIV, as assessed by the treating physician. Participants are
allocated to a “musical intervention” arm (“musical intervention” applied during all NIV sessions), to a “sensory
deprivation” arm (sight and hearing isolation during all NIV sessions), or to the control group. The primary endpoint
is the change in respiratory comfort (measured with a digital visual scale) before the initiation and after 30 minutes
of the first NIV session. The evaluation of the primary endpoint is performed blindly from the treatment group.
Secondary endpoints include changes in respiratory and cardiovascular parameters during NIV sessions, the
percentage of patients requiring endotracheal intubation, day-90 anxiety/depression and health-related quality of
life, post-trauma stress induced by NIV, and the overall assessment of NIV.
The follow-up for each participant is 90 days. We expect to randomize a total of 99 participants.
Discussion: As music intervention is a simple and easy-to-implement non-pharmacological technique, efficacious in
reducing anxiety in critically ill patients, it appeared logical to assess its efficacy in NIV, one of the most stressful
techniques used in the ICU. Patient centeredness was crucial in choosing the outcomes assessed.
Trial registration: ClinicalTrials.gov: NCT02265458. Registered on 25 August 2014.
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Acute respiratory failure (ARF) is the most frequent organ
failure in patients in the intensive care unit (ICU) [1].
Among the various respiratory supports, non-invasive
ventilation (NIV) allows the administration of a positive
pressure of air and oxygen, at a set inspiratory flow and
FiO2, which unloads respiratory muscles and enables
alveolar recruitment. NIV has shown its efficacy in acute
or chronic respiratory failure [2] and cardiac pulmonary
edema [3] in terms of intubation rates [4, 5], mortality [5],
and nosocomial infections [6]. These positive findings
have not been so clearly found in de novo ARF, where
NIV benefits may be outweighed by the risks of delaying
intubation [7, 8], which has been associated with increased
mortality [8]. Although NIV offers many undisputable
advantages over invasive ventilation, its intolerance is one
of its major drawbacks. Also, premature cessation of NIV
because of intolerance may lead to intubation in some
cases [7–9]. Hence, investigators have searched for means
of improving tolerance of the technique by increasing pa-
tient comfort. Light sedation has been shown to decrease
NIV-induced discomfort [10–13] and appears to be safe
and effective, but this alternative remains a pharmacologic
intervention requiring the administration of potentially
dangerous anesthetic drugs, such as propofol, remifenta-
nil, or dexmedetomidine. Among non-pharmacologic
interventions, sophrology, which aims at increasing well-
being through differential relaxation, has been assessed
with interesting results [14]. However, only a limited
number of patients have been evaluated, and the major
drawback is the need for patient adherence, a specific
caregiver’s training, and the presence of a single person
with the patient for an entire 30-minute session, which
makes it very dependent on the availability of the team.
Music therapy in health care settings has recently been
investigated. In the perioperative setting, it has shown
beneficial effects on anxiety, pain, analgesia use, and
patient satisfaction [15]. In the ICU, several studies
[16–19] and a recent meta-analysis [20] described its
effects in terms of anxiety and physiological changes
(heart rate, respiratory rate, and blood pressure) in
patients on invasive mechanical ventilation. These studies
showed that music therapy is feasible in the ICU, with
beneficial effects on physiological parameters, anxiety, and
agitation.
Study rationale
As anxiety is one of the major components of NIV
discomfort that leads to NIV cessation, we therefore
questioned the potential benefit of music therapy as a
non-pharmocological adjunct to NIV to enhance accept-
ance and tolerance of the technique.
As "music therapy" implies the intervention of a quali-
fied music therapist, we choose to use the term “musicalintervention,” which refers to a receptive music session
administered to a patient by trained caregivers. To distin-
guish the potential effect of an isolation from the ICU’s
noise and light nuisance, we decided to build a three-arm
trial, as performed in invasively ventilated ICU subjects by
Chlan et al. [17].
Study objectives
The primary objective of the present trial is to assess the
hypothesis that a musical intervention administered to
patients with ARF in the ICU improves NIV tolerance and
thereby their comfort and ventilation parameters after
30 minutes of NIV, in comparison to conventional care.
The secondary objectives are to assess musical interven-
tion effect on respiratory comfort and respiratory and
cardiovascular parameters during NIV sessions; on NIV
failure; on anxiety and agitation during NIV; anxiety/de-
pression and health-related quality of life; post-trauma
stress induced by NIV; and on overall assessment of NIV
in terms of discomfort, trauma, and satisfaction.
Methods/design
Design
Mus-IRA (MUSique pour l’Insuffisance Respiratoire
Aigue) is a prospective, multicenter, open-label, three-
arm randomized trial. This study is conducted in ICU
patients with ARF requiring NIV. Participants are allo-
cated either to an interventional arm or to the control
group. A musical intervention is applied during NIV ses-
sions in the first intervention arm. Participants included
in the second intervention arm undergo sight and
hearing isolation (sensory deprivation). Participants
included in the control arm receive conventional
treatment associated with NIV.
Definitions
“Non-invasive ventilation” refers to a bilevel positive
pressure ventilation applied via a non-invasive interface (a
face mask); “music intervention” refers to a receptive music
session administered to a patient by trained caregivers;
“respiratory comfort” refers to a “0” rate on a 10-cm
dyspnea visual analog scale; “NIV intolerance” refers to the
need for the premature cessation of an NIV session; “NIV
failure” is defined by the need of endotracheal intubation.
Ethical aspects
The ethics committee of the French Society for Intensive
Care Medicine (Commission d’Ethique de la Société de
Réanimation de Langue Française approval CE SRLF 14–
21) and the competent French authorities (Comité de
Protection des Personnes d’Île de France IV, Hôpital
Saint-Louis; registration number 2014-A00643-44; date of
approval 26 March 2015) approved the study protocol and
patient information documents. According to French law
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written informed consent is mandatory for inclusion and
randomization.
Participating ICUs
The three French participating units (Louis Mourier,
Gustave Roussy, and CHD de Vendée) have an expertise
in NIV. Nurses and nursing assistants have received
music intervention training by a skilled music therapist.
All participating ICU staff members have received train-
ing in the study procedures and protocols to provide the
musical intervention and standardized NIV sessions.
Study population
Eligible patients are adults (≥18 years of age), admitted
to the ICU for ARF or exhibiting an ARF during their
ICU stay, for whom the physician in charge considers
that NIV is indicated.
In each participating ICU, NIV-treated patients are
screened for eligibility by the staff members (investiga-
tors) 24 hours a day, 7 days a week.
Inclusion and exclusion criteria
The inclusion criteria are as follows:
– Adults (≥18 years of age)
– For whom the physician in charge considers that
NIV is indicated
– With a level of consciousness good enough
to benefit from the musical intervention
(Glasgow Coma Scale ≥12).
The non-inclusion criteria include:
– Patients with a classical contraindication to NIV
– Patients with severe hearing impairment
– Patients for whom a decision of withdrawal of
life-sustaining therapies has been made, and with an
estimated life expectancy of less than 48 hrs
– Patients included in another trial dealing with an
ARF treatment strategy.
Randomization
Eligible consecutive patients are randomly allocated to
one of the three study arms. Randomization and conceal-
ment are achieved using a centralized, secure, computer-
generated, interactive, web-response system accessible
from each study center (CleanWEB, Telemedicine
technologies S.A.S, Boulogne-Billancourt, France) [21].
The randomization is balanced by blocks of variable and
undisclosed size and stratified on the center and the
presence of a chronic respiratory insufficiency. Before
randomization, the presence of the inclusion criteria and
the absence of the non-inclusion criteria are verified andentered in the electronic case report form. In each ICU,
patients are enrolled by the local physicians and a clinical
research nurse and/or clinical research assistant. The
randomization day is the study day 1.
Blinding
For obvious reasons, this study cannot be blinded, either
on the patient’s side (receiving or not receiving head-
phones, and listening or not listening to music during
NIV sessions) or the caregiver’s side (helping the patient
to choose the music and to adjust the headphones and
the blinding mask). However, the evaluation of the
primary endpoint is performed blindly from the treat-
ment group according to the prospective randomized
open blinded endpoint (PROBE) method [22]. Indeed,
the primary endpoint is respiratory comfort after the
30 minutes of the first NIV session after randomization;
this endpoint is assessed by an independent person who
did not participate in the initiation of the NIV session
and has no knowledge of the actual treatment received
during the session. The organization of our ICUs allows
requiring a blinded evaluator such as a nurse or a nursing
assistant from another unit. The patient is told to not give
any clue about the randomization arm during the evalu-
ation. This same investigator will conduct assessments of
the following NIV sessions; as far as possible, his/her inde-
pendence with regard to the randomization group will be
maintained in subsequent NIV sessions.
Study interventions
The study protocol and the three randomization arms
are summarized on Fig. 1.
NIV conduction in all three groups
NIV is initiated according to standards of care and in
line with each participating ICU’s practices. The detailed
NIV protocol is given in Additional file 1. Briefly, masks
are chosen according to the patient's morphology, and
the physician in charge, along with the nurse and the
nursing assistant, initiates the first session.
Ventilator settings
Initial ventilator settings are chosen to maximize the
patient's tolerance and minimize air leaks, in order to
obtain a respiratory rate between 15 and 25 cycles per
minute, an exhaled tidal volume of 6–10 ml/kg of
predicted body weight, and the disappearance of signs of
respiratory distress. FiO2 is set to obtain a minimal pulse
oximetry of 92 %. The duration of NIV sessions is left to
the discretion of the physician in charge, based on the
patient’s needs.
Subsequent NIV sessions
Fig. 1 Study protocol and randomization arms. Pressure support is progressively increased in order to obtain a respiratory rate between 15 and
25 cycles per minute, an exhaled tidal volume of 6–10 ml/kg of predicted body weight, and the disappearance of signs of respiratory distress. Positive
end expiratory pressure is set 2–6 cm H2O above pressure support and adjusted according to patient’s tolerance. FiO2 is set to obtain a minimal pulse
oximetry of 92 %. NIV non-invasive ventilation, PS pressure support, RR respiratory rate, Vte exhaled tidal volume, PBW predicted body weight, FiO2
fraction of inspired oxygen, SpO2 peripheral capillary oxygen saturation, EPAP expiratory positive airway pressure, ICU intensive care unit
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nurse and nursing assistant according to a prespecified
timeline: the physician in charge prescribes the length of
NIV sessions and the number per day.
Patient monitoring during NIV sessions
All patients undergo careful monitoring to detect
and treat any complications related to ARF or NIV.
Criteria for intubation are those in use in the partici-
pating ICUs [23].
Control group: “NIV only”
In this group, NIV is conducted as detailed above.
Usually, the nurse and the nursing assistant provide
psychological support and relaxation care to help the
patient cope with NIV discomfort.
“Sensory deprivation” group
In this group, NIV is conducted similarly as for the former
group but with the addition of sensory deprivation.
Sensory deprivation consists of isolating participants from
the noise and lights of the ICU:
– An insulating around-ear headphone (BOSE AE2®,
the same as that used in the latter intervention arm)is placed on the patients’ ears by the unblinded care-
givers, once the NIV mask has been fitted and the
ventilator settings optimized.
– Applying a sleeping mask conceals the eyes. If the
patient does not tolerate being blindfolded (e.g., due
to claustrophobia), alternative solutions are
suggested to the patient (such as closing his eyes or
using a personal scarf ) to make him feel at ease. The
purpose of the visual deprivation is to avoid the
patient being disrupted from the relaxation process
because of visual distractions.
The headphones and mask will be left in place for
30 minutes. Data regarding tolerance and possible
rejection of sensory deprivation will be collected.
After inclusion, all NIV sessions are conducted as
detailed above until NIV discontinuation, day 28, or ICU
discharge.
“Musical intervention" group
NIV is conducted as detailed above, including visual
isolation. The musical intervention is initiated starting
from the first NIV session that follows randomization.
– Once the NIV mask has been fitted and the
ventilator settings optimized, the trained nurse or
Messika et al. Trials  (2016) 17:450 Page 5 of 13nursing assistant sets up the headphones
(BOSE AE2®), presents the tablet interface
(Samsung Galaxy®), and shows the patient
how to handle it.
– The patient’s musical tastes are determined by a
caregiver-administered questionnaire, either to the
patient or to her relatives if the patient is unable
to express her musical choices (moderate
impairment of consciousness). The patient
therefore chooses the musical program, with
MUSIC CARE© software [19, 24, 25], according
to her musical preferences, sets the volume level,
and runs the musical session.
– The musical intervention session lasts 30 minutes
and contains two phases, called an L-type sequence
(Fig. 2) [24]; the downswing phase is achieved by
reducing the musical rhythms starting at high
tempos and a high number of instruments, gradually
leading to slower tempos and reducing the number
of instruments, the frequencies, and the volume.
Then the patient is moved through a maximum
relaxation phase with a slow-paced rhythm and
reduced orchestras, resulting in maximum
relaxation (bottom of the “L”).
– If the patient asks for more than 30 minutes of
musical intervention, the session is extended
towards a ”U-type” [25].Fig. 2 Musical intervention with the L-type sequence [24]. This
sequence begins with a downswing phase, achieved by reducing
the musical rhythms and the number of instruments, the frequencies,
and the volume, and a maximum relaxation phase with a slow-paced
rhythm and reduced orchestras (bottom of the L). bpm beats per minuteAfter inclusion until NIV discontinuation, day 28, or
ICU discharge, all NIV sessions are performed according
to this mode.
Data collection and follow-up
Collected data at each time are summarized in the
SPIRIT schedule of events shown in Table 1.
At day 1 (baseline)
Demographic data and medical history, including the
current clinical history with the reason for ICU admission,
Simplified Acute Physiology Score III severity score [26],
and Sequential Organ Failure Assessment score [27], are
collected.
Treatments including NIV (and its settings), fluid ther-
apy, catecholamine infusion, and endotracheal intubation
are recorded. Laboratory tests include serum (and urine if
diuresis is present) electrolyte levels determination, serum
glucose level, urea and creatinine concentration, and arter-
ial blood gas determination. Respiratory and hemodynamic
parameters before the beginning of the NIV session
(respiratory rate, exhaled tidal volume, PaO2/FiO2 ratio,
heart rate, arterial pressure) are collected.
The research team administers to the patient, or to a
proxy if the patient is not able to answer, the baseline
Hospital Anxiety and Depression Scale (HADS) ques-
tionnaire [28] and Short Form-36 (SF-36) [29] in order
to determine the baseline health-related quality of life.
At each NIV session, until NIV discontinuation or day 28
The prescribed duration of the NIV session is recorded.
Prior to each NIV session, immediately after NIV is
correctly set (5 minutes), at 30 minutes, and at 1, 2, 3, 4,
6, 8, 12, 16, 20, 24 hours depending on the length of
each NIV session, and at the end of the session, the
following data are collected:
– Respiratory comfort assessed by a blinded evaluator
(nurse from another unit) with the use of a numeric
visual scale [14]
– The same respiratory and hemodynamic parameters
as the initial ones
– Agitation assessed by Richmond Agitation-Sedation
Scale [30].
For each NIV session, the need for physical contention
or sedative or anxiolytic treatments is assessed and
recorded. The tolerance of sensory isolation is recorded,
as well as attempts to pull off the NIV mask or head-
phones. At the end of each session, data for its exact
duration, the reason of its premature ending if appropri-
ate, and the need for endotracheal intubation are
collected. Furthermore, arterial blood gases are reported
when these tests are performed as clinically indicated.
Table 1 Summary of collected data at each time point according to SPIRIT 2013 guidelines
Study period
Enrollment Allocation Post-allocation — at each NIV session NIV discontinuation, ICU
discharge or day 28
Close-out
Day 90
Time point t1 beginning of NIV session t2(t1 + 5 min) t3(t1 + 30 min) t4(t1 + 1 h) tx










Baseline variables: Demographic data




X X X X X X X
Respiratory and hemodynamic
parameters
X X X X X X X
Ongoing therapies: Catecholamine
infusion, need for ETI, attempts to
pull out NIV mask, headphones or
sensory isolation, need for physical
contention, sedative or anxiolytic
treatments, NIV complication
X X
Health-related quality of life
(HADS and SF-36 scores)
X X
Length of ICU and hospital stay X
Vital status, NIV satisfaction, comfort
and associated trauma, IES-R for NIV
X X
Decision to withhold life-sustaining
therapies
X
NIV non-invasive ventilation, ETI endotracheal intubation, HADS Hospital Anxiety and Depression Scale [28], IES-R Impact of Event Scale - Revised [31], RASS Richmond Agitation-Sedation Scale [30], SAPS III Simplified
Acute Physiological Score III [26], SF-36 Short Form-36 [29], SOFA Sequential Organ Failure Assessment [27]
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also recorded. For the “musical intervention” group, the
type of music chosen and the feeling experienced during
the session are recorded.At NIV discontinuation, ICU discharge, or day 28
Apart from endotracheal intubation, the need for trache-
ostomy during the ICU stay and vital status at ICU
discharge are recorded. Patients are surveyed for
numeric scaling of NIV satisfaction, NIV comfort, and
NIV-associated trauma. The Impact of Event Scale -
Revised (IES-R) [31] is applied to NIV.At day 90
Vital status is regularly updated for each patient until the
end of the study. In order to determine the 3-months
health-related quality of life, numeric scaling of NIV satis-
faction, NIV comfort, and NIV-associated trauma, the
IES-R applied to NIV, and the HADS questionnaire [28]
and SF-36 [29] are determined and recorded by a blinded-
to-randomization group research staff member through a
phone survey of patients who are alive.Organization of the trial
Funding/support
The Mus-IRA trial is sponsored by the Assistance
Publique - Hôpitaux de Paris and supported by a grant of
the French Ministry of Health dedicated to nursing care
(Programme Hospitalier de Recherche Infirmière et
Paramédicale 2013; PHRIP 13–453).Coordination and implementation of the trial
Each medical and paramedical team of the three participat-
ing ICUs was trained in the protocol and data collection
using the electronic case report form (eCRF) during formal
meetings prior to the start of screening and inclusion. The
eCRF is developed with CleanWEB™, a centralized, secure,
interactive, web-response system accessible from each
study center, provided and managed by Telemedicine
technologies.
Local physicians and clinical research assistants in
each participating ICU are responsible for daily screen-
ing and inclusion of patients, compliance with protocol,
availability of data requested for the trial, and comple-
tion of the eCRF. In accordance with French law, the
eCRF and database were validated by appropriate com-
mittees (CCTIRS: Comité Consultatif sur le Traitement
de l'Information en matière de Recherche dans le
domaine de la Santé; CNIL: Commission Nationale de
l'Informatique et des Libertés).Study endpoints
Primary endpoint
The primary endpoint is the change in respiratory
comfort before the initiation and after 30 minutes of the
first NIV session after randomization. The respiratory
comfort will be measured using a digital visual scale
[14]. This scale is a 10-cm long ruler, shaped like an
arrow. It is bounded on the left by “0: no respiratory
discomfort” (the smaller base of the arrow) and on the
right by “10: maximal respiratory discomfort” (the larger
base of the arrow).
The participant marks the level of his/her perception
of discomfort directly on the ruler.
Secondary endpoints
Secondary endpoints are:
– The evolution of respiratory comfort during the first
session of NIV evaluated before initiation, after 5
and 30 minutes, and at 1, 2, 3, 4, 6, 8, 12, 16, 20,
24 hours depending on the length of each NIV
session, and at the end of the session
– The evolution of respiratory comfort evaluated at
the same times in each subsequent session,
measured using a digital visual scale [14]
– Changes in respiratory parameters during NIV
sessions (respiratory rate, transcutaneous oxygen
saturation, exhaled tidal volume) at 5 and
30 minutes and at 1, 2, 3, 4, 6, 8, 12, 16, 20,
24 hours depending on the length of each NIV
session and at the end of the session
– Changes in cardiovascular parameters during NIV
sessions (heart rate, arterial pressure) at 5 and
30 minutes and at 1, 2, 3, 4, 6, 8, 12, 16, 20,
24 hours depending on the length of each NIV
session and at the end of the session
– The percentage of patients requiring endotracheal
intubation (NIV failure) at the end of an NIV session
– The adequacy of the prescribed NIV session
duration and its actual duration
– The number of sessions interrupted before the
end of the prescribed time
– The percentage of patients requiring physical
contention, sedative, or anxiolytic treatments
during NIV sessions and ICU stay
– Anxiety/depression and health-related quality of life
evaluated by HADS and SF-36 scores at baseline and
after 3 months
– Post-trauma stress induced by NIV, measured with
the IES-R scale immediately at discontinuation of
NIV session and after 3 months of inclusion
– The overall assessment of NIV (in terms of
discomfort, satisfaction, and trauma) at the
discontinuation of NIV and at day 90.
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Sample size calculation
The assumptions used to calculate the number of partici-
pants for the study were determined from the article by
Constantin et al. [14]. In that prospective, randomized,
controlled trial assessing the "impact of sophrology on the
tolerance of NIV sessions in patients with ARF," the differ-
ence in respiratory discomfort between patients treated
with sophrology and the control group was 2.8, with a
standard deviation of 2.5.
For our study, we considered the same standard devi-
ation but a less optimistic difference for the comparison
of the “sensory deprivation” group and the “musical
intervention" group. Seventy-eight participants (26 par-
ticipants per arm) should be included to obtain a power
of 80 % to demonstrate a difference of 2 units of respira-
tory discomfort between the two groups, with an alpha
risk of 5 % (bilateral formulation).
Three comparisons will be performed to assess the
primary endpoint: a comparison between "musical
intervention" and “sensory deprivation," a comparison
between "musical intervention" and "NIV alone," and a
comparison between "sensory deprivation" and "NIV
only." If the three comparisons were each performed
with a significance level of 5 %, the overall type I error
rate would be far above the nominal level (14 %). To
maintain an overall type I error rate of 5 % in a strong
sense, we will apply a non-parametric Bonferroni-based
chain procedure [32] for the analysis (as explained in the
following section on statistical analysis), which implies
reducing the significance level of two comparisons at
2.5 %. In order to maintain a power of 80 %, the number
of planned participants was increased to 93 in total
(31 per arm).
Total planned sample size
To take into account a potential loss to follow-up of
about a 5 % rate for the primary endpoint, we expect to
randomize a total of 99 participants (33 per arm).
Statistical analysis
A flow chart will describe the number of eligible patients
and the number of patients actually included (in total
and per arm). For each group and at each assessment
date, qualitative variables will be described in terms of
number and percentage, and quantitative variables in
terms of number, mean, and standard deviation. Quantita-
tive variables with skewed distribution will be presented in
terms of median and interquartile range (25th–75th
percentile).
Primary endpoint
The change in respiratory comfort at initiation and after
30 minutes of the first NIV session will be analyzed inthe intention-to-treat population. For each patient, the
variation in respiratory comfort will be calculated by the
difference between the measurement at “30 minutes”
and "before." This change will then be compared
between the treatment groups, based on a Student’s t
test. If the test application conditions are not met, a
Wilcoxon test will be applied.
Because three parallel groups are included in the study,
three comparisons are possible: "musical intervention" and
"NIV only" (comparison 1), "sensory deprivation" and
"NIV only" (comparison 2), and "musical intervention"
and "sensory deprivation" (comparison 3). These compari-
sons will be performed in a pre-established hierarchical
test procedure (see Fig. 3), in order to maintain the alpha
risk of 5 % in a strong sense:
 Step 1: We will perform comparisons 1 and 2, both
at 2.5 % (bilateral) alpha risk.
 Step 2: In the event of non-significance of the two
previous tests, we will stop the test procedure and
conclude the negativity of the trial; in the case of
statistical significance of both previous tests, we will
perform comparison 3 at 5 % (bilateral) alpha risk;
in the case of statistical significance of only one of
the two previous tests, we will perform comparison
3 at 2.5 % (bilateral) alpha risk.
 Step 3: If comparison 3 was performed at 2.5 %
alpha risk and is significant, the non-significant
comparison performed in step 1 may be performed
again at an alpha risk of 5 % (Fig. 3).Other analyses
All secondary analyses will be performed in the intention-
to-treat population (all randomized patients) and also in
the per protocol population (patients with no major devi-
ation of the protocol) at a bilateral 5 % alpha risk.
Unless otherwise specified, categorical variables will be
compared by a chi-squared test or Fisher test as appro-
priate. Continuous variables will be compared by a
Student's t test or Wilcoxon test as appropriate (when
two groups are compared) and by an analysis of variance
(ANOVA) or Kruskal-Wallis test as appropriate (when
more than two groups are compared).Adjusting the analysis of the primary endpoint for
potential confounders The primary endpoint analysis
will be adjusted on the stratification factors (centers and
underlying chronic respiratory disease) and on potential
confounders using a multivariate analysis (linear regres-
sion model). Potential confounders will be: a prior chronic
respiratory disease; a PaO2/FiO2 < 200 mmHg; a prior
psychiatric disease.
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population The change in respiratory comfort at
initiation and after 30 minutes of the first NIV session
between the groups will also be compared in the per
protocol population defined previously (this comparison
does not constitute the primary analysis of the study).Evolution of respiratory comfort during NIV sessions
The number of measures of respiratory comfort for each
patient will be variable, since the duration and number
of NIV sessions is at the discretion of the physician. The
data structure is complex and has three levels:
– Level 1: respiratory discomfort measures
– Level 2: patients
– Level 3: centers.
For this type of (repeated) data, it is essential to take
into account correlations between measurements from
the same patient. A linear mixed effects model (including
fixed and random effects) will be used to model the effect
of the three interventions on the evolution of respiratory
comfort during NIV sessions. This model will include:
 Fixed effects
○ The variable "time"
○ The randomization group (categorical variable
with three different levels) and its interaction
with time
○ Stable characteristics over time (see potential
confounders described above)
○ Characteristics which vary over time: the
number of NIV sessions
 Random effects ("subject effect").
The need for a model with random intercept and slope
(versus random intercept only) will be assessed at the
time of the analysis with a likelihood ratio test. An
appropriate modeling of time will be performed if its
effect is not linear.
Correlations between patients from the same center
could also be taken into account by the inclusion of a
"random center effect" (level 3). However, such a mixed
model may be unsuitable in practice because of the
limited number of clusters (only three participating
centers). In this setting, it is preferable to include a fixed
center effect [33], and this is the solution that will be
implemented in this analysis.Evolution of respiratory and hemodynamic parameters
during NIV sessions This analysis will be conducted
according to the same principles as for the analysis of
the evolution of respiratory comfort.Adequacy of prescribed and observed NIV sessions
duration For this analysis, we will first calculate for each
patient the ratio of the sum of the observed durations of
NIV sessions and the sum of the prescribed durations.
This ratio will reflect the compliance of each patient
with the prescription. Compliance will be compared
between groups by the usual tests for comparing a
continuous outcome.
Number of interrupted sessions before the end of the
prescribed duration The number of interrupted
sessions is a count outcome variable. The comparison
groups will therefore be based on a Poisson regression
model, introducing the randomization group as an
explanatory variable and an "offset" variable (whose
coefficient is not estimated and is fixed to 1) representing
the number of prescribed sessions for each patient.
Percentage of patients requiring physical restraints
or administration of anxiolytics or sedatives during
NIV sessions, percentage of intubated patients These
percentages will be compared between groups by the
usual tests for comparing proportions.
SF-36, HADS scores, IES-R scores, and overall
assessment of NIV between inclusion and day 90 The
evolution of these scores between baseline and day 90
(difference between the measurement at 3 months and
inclusion) will be compared between groups by the usual
tests comparing continuous variables.
Missing data
First, all analyses will be performed without taking into
account missing values. Second, a sensitivity analysis will
be performed using multiple imputations to replace
missing values where appropriate for primary and all
secondary outcomes [34]. We will create 10 copies of
the dataset, with the missing values replaced by imputed
values, based on observed data including outcomes and
baseline characteristics of participants. Each dataset will
be analyzed using standard statistical methods, and the
results from each dataset will be pooled into a final
result using Rubin’s rule.
Software
The analyses will be performed using R software (R
Foundation for Statistical Computing, Vienna, Austria,
http://www.R-project.org/) 3.0 or later or SAS version
9.2 or later.
Safety considerations
In the current study there are no anticipated risks or
inconveniences. For this reason, neither safety interim
analysis nor stopping rules are planned. Any unexpected
Fig. 3 Hierarchical test procedure used for the primary endpoint analysis
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be recorded on the individual CRFs. Unexpected serious
adverse events (SAEs) will be reported to the sponsor im-
mediately, and all participating centers will be informed
by the sponsor (Department de la Recherche Clinique -
Assistance Publique - Hôpitaux de Paris).
Discussion
In this randomized controlled trial, we expect an improve-
ment of NIV tolerance and efficacy thanks to a simple,
easily implemented, non-pharmacological intervention.
In everyday life, medical teams strive to improve pa-
tients’ care, and patient centeredness is crucial to quality
of care [35]. Intolerance is one of NIV’s major drawbacks
and has been associated with a higher risk of intubation
[7–9]. In the study of Delclaux et al. of NIV patients
with hypoxemic ARF [8], intolerance was responsible for
14 % of NIV failures, leading to intubation in a third of
them, a finding shared by others [9]. In order to improve
NIV tolerance, ventilators have been bench-marked, and
their performances rated [36–38]. Likewise, physicianshave focused their efforts on assessing appropriate hu-
midification devices [39] and ventilator-patient interface
types [40], and on reducing associated leaks [41]. Beyond
these technical aspects, however, patient-centered out-
comes may have been overlooked and must be taken
into account.
This trial involves patient-centered care at two different
levels. First, the patient is active in choosing the desired
music type, which may maximize his/her adherence to the
music intervention, as suggested by Chlan et al. with the
use of a music preference assessment questionnaire [17].
Second, to evaluate music intervention efficacy, we de-
fined a patient-reported measure as the primary outcome
(variation of dyspnea discomfort) and as secondary
outcomes (anxiety/depression and health-related quality
of life at baseline and at day 90; post-trauma stress
induced by NIV, at discontinuation of NIV session, and at
day 90; the assessment of NIV discomfort, satisfaction,
and trauma).
We have chosen to run this trial in three units that
already provided patient-centered care, in particular
Messika et al. Trials  (2016) 17:450 Page 11 of 13regarding relatives’ visitation hours, patients’ comfort
needs, and involvement of patients and their relatives in
the decision-making process.
Music therapy has shown its beneficial effects on
patient anxiety, pain [24], and physiological events
(heart rate, blood pressure) either outside [15, 42–44]
or inside the ICU [16–20]. These studies showed that
music therapy is feasible in the ICU, although only a
small proportion of invasively ventilated patients (5.3 %)
might benefit from such an intervention [17]. As such,
music effects have never been assessed during NIV, a
ventilator mode increasingly used in the ICU [45].
Therefore, one may surmise that many more patients
will be affected by this intervention. Given that anxiety
is one of NIV’s major drawbacks, our aim is to de-
crease potential stressful feelings that might be induced
by NIV with the music therapy. This has been shown
in the ICU: Han et al. [18] showed that a single music
session significantly decreased anxiety (measured by the
Spielberger State/Trait Anxiety Inventory) in patients
invasively ventilated, compared to those who did not
receive music. Likewise, Chlan et al. showed a signifi-
cant effect of patient-directed music therapy on redu-
cing anxiety (measured by a visual analog scale)
compared with usual care during ICU stays in patients
being ventilated [17].
It has been shown that post-ICU symptoms of anx-
iety, depression, or post-traumatic stress disorder
(PTSD), especially in NIV patients [46], might occur
up to 90 days after an ICU stay. Unfortunately, these
symptoms were not assessed after this time in previ-
ous studies of music intervention, and never in NIV
patients. In our trial, we plan to evaluate these
symptoms and to find if a punctual intervention (i.e.,
30 minutes of music intervention during NIV
sessions) can diminish such post-ICU symptoms.
Short- and long-term assessment of NIV-related
PTSD seems necessary to determine the length of
action of the interventions being tested.
Chlan et al. evidenced that music administration led
to significantly less anxiety and sedation intensity
compared to usual care in ventilated patients. But this
was not evidenced when comparing usual care to
noise-canceling headphones. We therefore decided to
build a three-arm trial in order to distinguish the ef-
fects of the music and of the isolation of the noise
and the light of the ICU. As ICU patients report
noise as the main source of discomfort [47], we
naturally question in our trial the role of noise isola-
tion and of music in NIV (and ICU) tolerance, and
therefore tested the “sensory deprivation” strategy.
To conclude, our trial tests an original non-
pharmacologic, simple, and toxin-free therapy to im-
prove one of the most stressful situations in the ICU.We deliberately choose patient-centered outcomes to
assess this patient-centered intervention.
Trial status
Enrollment is ongoing. Inclusions started on May 2015
and are expected to be completed in May 2016.
Additional files
Additional file 1: NIV protocol. (DOCX 103 kb)
Additional file 2: SPIRIT guidelines checklist. (DOC 121 kb)
Abbreviations
ARF: Acute respiratory failure; CCTIRS: Comité Consultatif sur le Traitement de
l'Information en matière de Recherche dans le domaine de la Santé; CE
SRLF: Commission d’Ethique de la Société de Reanimation de Langue
Française; CNIL: Commission Nationale de l'Informatique et des Libertés;
eCRF: Electronic case report form; FiO2: Fraction of inspired oxygen;
HADS: Hospital Anxiety and Depression Scale; IES-R: Impact of Event Scale -
Revised; ICU: Intensive care unit; NIV: Non-invasive ventilation; PaO2: Arterial
oxygen partial pressure; PHRIP: Programme Hospitalier de Recherche
Infirmière et Paramédicale; SAPS: Simplified Acute Physiology Score;
SF-36: Short Form-36; SOFA: Sequential Organ Failure Assessment
Acknowledgements
This study is sponsored by the Assistance Publique - Hôpitaux de Paris
and funded by a grant of the French Ministry of Health dedicated to
nursing care (Programme Hospitalier de Recherche Infirmère et
Paramédicale 2013; PHRIP 13–453). We wish to thank MUSIC CARE© for
their help in performing the study. We are indebted to the nurses and
the nursing assistants at the three centers for their commitment to and
participation in the study.
Authors' contributions
JM, JDR, and DH drafted the manuscript. JM, DH, NP, SV, SGu, AF, AD, and
JDR participated in the design of the Mus-IRA study and contributed to
revisions of the original manuscript. DH performed the statistical plan
and sample size calculation. JM, DH, NP, SV, YM, ER, AB, JR, NM, AS, CP,
SGu, AD, AF, SGa, DD, and JDR are involved in acquisition of data,
edited the manuscript, and read and approved the final manuscript.
Competing interests
Stéphane Guétin is the chief executive officer of MUSIC CARE©, which
provided the music intervention software available on the tablets. The
other authors have no competing interest in the manuscript.
Author details
1AP-HP, Hôpital Louis Mourier, Réanimation Médico-chirurgicale, 178 rue des
Renouillers, F-92700 Colombes, France. 2Université Paris Diderot, Sorbonne
Paris Cité, IAME, UMRS 1137, F-75018 Paris, France. 3INSERM, IAME, U1137,
F-75018 Paris, France. 4Université Paris Diderot, Sorbonne Paris Cité, ECEVE,
UMRS 1123, F-75010 Paris, France. 5INSERM, ECEVE, U1123, F-75010 Paris,
France. 6INSERM, CIC-EC 1425, UMR 1123, F-75010 Paris, France. 7APHP,
Hôpital Louis Mourier, Département d’Epidémiologie et Recherche Clinique,
178 Rue des Renouillers, Colombes F-92700, France. 8Université Paris Diderot,
UMR 1123, Sorbonne Paris Cité, Paris, France. 9Centre Hospitalier
Départemental de Vendée, Réanimation Médico-Chirurgicale, La
Roche-sur-Yon F-85925 Cedex 9, France. 10Institut Gustave Roussy,
Réanimation Médico-chirurgicale, Villejuif F-94800, France. 11CHRU de
Montpellier, Service de Neurologie, Inserm U1061, Montpellier F-34000,
France. 12Present address: Réanimation Médico-chirurgicale, Hôpital Louis
Mourier, 178 rue des Renouillers, F-92700 Colombes, France.
Received: 17 December 2015 Accepted: 26 August 2016
Messika et al. Trials  (2016) 17:450 Page 12 of 13References
1. Demoule A, Girou E, Richard JC, Taille S, Brochard L. Increased use of
noninvasive ventilation in French intensive care units. Intensive
Care Med. 2006;32:1747–55.
2. Brochard L, Mancebo J, Wysocki M, Lofaso F, Conti G, Rauss A, et al.
Noninvasive ventilation for acute exacerbations of chronic obstructive
pulmonary disease. N Engl J Med. 1995;333:817–22.
3. L’Her E, Duquesne F, Girou E, de Rosiere XD, Le Conte P, Renault S, et al.
Noninvasive continuous positive airway pressure in elderly cardiogenic
pulmonary edema patients. Intensive Care Med. 2004;30:882–8.
4. Park M, Sangean MC, Volpe MS, Feltrim MIZ, Nozawa E, Leite PF, et al.
Randomized, prospective trial of oxygen, continuous positive airway
pressure, and bilevel positive airway pressure by face mask in acute
cardiogenic pulmonary edema. Crit Care Med. 2004;32:2407–15.
5. Ram FSF, Picot J, Lightowler J, Wedzicha JA. Non-invasive positive pressure
ventilation for treatment of respiratory failure due to exacerbations of
chronic obstructive pulmonary disease. Cochrane Database Syst. Rev.
2004;CD004104
6. Girou E, Brun-Buisson C, Taillé S, Lemaire F, Brochard L. Secular trends in
nosocomial infections and mortality associated with noninvasive ventilation
in patients with exacerbation of COPD and pulmonary edema. JAMA.
2003;290:2985–91.
7. Antonelli M, Conti G, Moro ML, Esquinas A, Gonzalez-Diaz G, Confalonieri M,
et al. Predictors of failure of noninvasive positive pressure ventilation in
patients with acute hypoxemic respiratory failure: a multi-center study.
Intensive Care Med. 2001;27:1718–28.
8. Delclaux C, L’Her E, Alberti C, Mancebo J, Abroug F, Conti G, et al.
Treatment of acute hypoxemic nonhypercapnic respiratory insufficiency
with continuous positive airway pressure delivered by a face mask: a
randomized controlled trial. JAMA. 2000;284:2352–60.
9. Carlucci A, Richard JC, Wysocki M, Lepage E, Brochard L. Noninvasive versus
conventional mechanical ventilation. An epidemiologic survey. Am J Respir
Crit Care Med. 2001;163:874–80.
10. Clouzeau B, Bui HN, Guilhon E, Grenouillet-Delacre M, Leger MS, Saghi T,
et al. Fiberoptic bronchoscopy under noninvasive ventilation and propofol
target-controlled infusion in hypoxemic patients. Intensive Care Med.
2011;37:1969–75.
11. Constantin JM, Schneider E, Cayot-Constantin S, Guerin R, Bannier F, Futier
E, et al. Remifentanil-based sedation to treat noninvasive ventilation failure:
a preliminary study. Intensive Care Med. 2007;33:82–7.
12. Akada S, Takeda S, Yoshida Y, Nakazato K, Mori M, Hongo T, et al. The
efficacy of dexmedetomidine in patients with noninvasive ventilation: a
preliminary study. Anesth Analg. 2008;107:167–70.
13. Devlin JW, Al-Qadheeb NS, Chi A, Roberts RJ, Qawi I, Garpestad E, et al.
Efficacy and safety of early dexmedetomidine during noninvasive
ventilation for patients with acute respiratory failure: a randomized,
double-blind, placebo-controlled pilot study. Chest. 2014;145:1204–12.
14. Constantin JM, Perbet S, Futier E, Cayot-Constantin S, Gignac V, Bannier F,
et al. Impact of sophrology on non-invasive ventilation tolerance in patients
with acute respiratory failure. Ann Fr Anesth Reanim. 2009;28:215–21.
15. Hole J, Hirsch M, Ball E, Meads C. Music as an aid for postoperative recovery
in adults: a systematic review and meta-analysis. The Lancet [Internet].
2015 [cited 2015 Aug 21]; http://linkinghub.elsevier.com/retrieve/pii/
S0140673615601696. Accessed 21 Aug 2015.
16. Dijkstra BM, Gamel C, van der Bijl JJ, Bots ML, Kesecioglu J. The effects of
music on physiological responses and sedation scores in sedated,
mechanically ventilated patients. J Clin Nurs. 2010;19:1030–9.
17. Chlan LL, Weinert CR, Heiderscheit A, Tracy MF, Skaar DJ, Guttormson JL,
et al. Effects of patient-directed music intervention on anxiety and sedative
exposure in critically ill patients receiving mechanical ventilatory support: a
randomized clinical trial. JAMA. 2013;309:2335–44.
18. Han L, Li JP, Sit JW, Chung L, Jiao ZY, Ma WG. Effects of music intervention on
physiological stress response and anxiety level of mechanically ventilated
patients in China: a randomised controlled trial. J Clin Nurs. 2010;19:978–87.
19. Jaber S, Bahloul H, Guetin S, Chanques G, Sebbane M, Eledjam JJ. Effects of
music therapy in intensive care unit without sedation in weaning patients
versus non-ventilated patients. Ann Fr Anesth Reanim. 2007;26:30–8.
20. Bradt J, Dileo C. Music interventions for mechanically ventilated patients.
In: The Cochrane Collaboration, editor. Cochrane Database Syst. Rev.
[Internet. Chichester: John Wiley & Sons, Ltd; 2014. [cited 2015 Aug 21].
http://doi.wiley.com/10.1002/14651858.CD006902.pub3.21. Kuchinke W, Ohmann C, Yang Q, Salas N, Lauritsen J, Gueyffier F, et al.
Heterogeneity prevails: the state of clinical trial data management in
Europe — results of a survey of ECRIN centres. Trials. 2010;11:79.
22. Hansson L, Hedner T, Dahlof B. Prospective randomized open blinded
end-point (PROBE) study. A novel design for intervention trials. Prospective
Randomized Open Blinded End-Point. Blood Press. 1992;1:113–9.
23. Antonelli M, Conti G, Rocco M, Bufi M, De Blasi RA, Vivino G, et al. A
comparison of noninvasive positive-pressure ventilation and conventional
mechanical ventilation in patients with acute respiratory failure.
N Engl J Med. 1998;339:429–35.
24. Guetin SGP, Blayac JP, Eledjam JJ. Une nouvelle technique contrôlée de
musicothérapie dans la prise en charge des douleurs viscérales aiguës et
chroniques. Doul Analg. 2005;8(1):19–25.
25. Guetin S, Ginies P, Siou DK, Picot MC, Pommie C, Guldner E, et al. The
effects of music intervention in the management of chronic pain: a
single-blind, randomized, controlled trial. Clin J Pain. 2012;28:329–37.
26. Metnitz PG, Moreno RP, Almeida E, Jordan B, Bauer P, Campos RA, et al.
SAPS 3 — From evaluation of the patient to evaluation of the intensive
care unit. Part 1: Objectives, methods and cohort description.
Intensive Care Med. 2005;31:1336–44.
27. Vincent JL, Moreno R, Takala J, Willatts S, De Mendonca A, Bruining H, et al.
The SOFA (Sepsis-related Organ Failure Assessment) score to describe organ
dysfunction/failure. On behalf of the Working Group on Sepsis-Related
Problems of the European Society of Intensive Care Medicine. Intensive
Care Med. 1996;22:707–10.
28. Zigmond AS, Snaith RP. The hospital anxiety and depression scale. Acta
Psychiatr Scand. 1983;67:361–70.
29. Ware JE, Sherbourne CD. The MOS 36-item short-form health survey (SF-36).
I. Conceptual framework and item selection. Med Care. 1992;30:473–83.
30. Chanques G, Jaber S, Barbotte E, Verdier R, Henriette K, Lefrant JY, et al.
Validation of the French translated Richmond vigilance-agitation scale.
Ann Fr Anesth Reanim. 2006;25:696–701.
31. Weiss DS, Marmar CR. The Impact of Event Scale - Revised. In: Wilson J,
Keane TM, editors. Assessing psychological trauma and PTSD. New York:
Guilford; 1996. p. 399–411.
32. Boutron I, Moher D, Altman DG, Schulz KF, Ravaud P. Extending the
CONSORT statement to randomized trials of nonpharmacologic treatment:
explanation and elaboration. Ann Intern Med. 2008;148:295–309.
33. Demidenko. Mixed models: theory and applications. New York: Wiley; 2012.
34. Sterne JAC, White IR, Carlin JB, Spratt M, Royston P, Kenward MG, et al.
Multiple imputation for missing data in epidemiological and clinical
research: potential and pitfalls. BMJ. 2009;338:b2393.
35. Tzelepis F, Sanson-Fisher R, Zucca A, Fradgley E. Measuring the quality of
patient-centered care: why patient-reported measures are critical to reliable
assessment. Patient Prefer Adherence. 2015;9:831.
36. Richard J-C, Carlucci A, Breton L, Langlais N, Jaber S, Maggiore S, et al.
Bench testing of pressure support ventilation with three different
generations of ventilators. Intensive Care Med. 2002;28:1049–57.
37. Carteaux G, Lyazidi A, Cordoba-Izquierdo A, Vignaux L, Jolliet P, Thille AW, et
al. Patient-ventilator asynchrony during noninvasive ventilation: a bench
and clinical study.Chest. 2012;142(2):367-376
38. Tassaux D, Strasser S, Fonseca S, Dalmas E, Jolliet P. Comparative bench
study of triggering, pressurization, and cycling between the home
ventilator VPAP II and three ICU ventilators. Intensive Care Med. 2002;
28:1254–61.
39. Lellouche F, L’Her E, Abroug F, Deye N, Rodriguez PO, Rabbat A, et al.
Impact of the humidification device on intubation rate during noninvasive
ventilation with ICU ventilators: results of a multicenter randomized
controlled trial. Intensive Care Med. doi:10.1007/s00134-013-3145-Z.
2013;1–9. LA – English
40. Navalesi P, Fanfulla F, Frigerio P, Gregoretti C, Nava S. Physiologic evaluation
of noninvasive mechanical ventilation delivered with three types of masks
in patients with chronic hypercapnic respiratory failure. Crit Care Med.
2000;28:1785–90.
41. Schettino GP, Tucci MR, Sousa R, Valente Barbas CS, Passos Amato MB,
Carvalho CR. Mask mechanics and leak dynamics during noninvasive
pressure support ventilation: a bench study. Intensive Care Med.
2001;27:1887–91.
42. Bradt J, Dileo C, Grocke D, Magill L. Music interventions for improving
psychological and physical outcomes in cancer patients. Cochrane Database
Syst Rev. 2011;CD006911.
Messika et al. Trials  (2016) 17:450 Page 13 of 1343. Ottaviani S, Bernard JL, Bardin T, Richette P. Effect of music on anxiety
and pain during joint lavage for knee osteoarthritis. Clin Rheumatol.
2011;31:531–4.
44. Bechtold ML, Puli SR, Othman MO, Bartalos CR, Marshall JB, Roy PK. Effect of
music on patients undergoing colonoscopy: a meta-analysis of randomized
controlled trials. Dig Sci. 2009;54:19–24.
45. Demoule A, Chevret S, Carlucci A, Kouatchet A, Jaber S, Meziani F, et al.
Changing use of noninvasive ventilation in critically ill patients: trends over
15 years in francophone countries. Intensive Care Med. 2016;42:82–92.
46. Azoulay E, Kouatchet A, Jaber S, Lambert J, Meziani F, Schmidt M, et al.
Noninvasive mechanical ventilation in patients having declined tracheal
intubation. Intensive Care Med 2013;39:292–301.
47. Novaes MA, Knobel E, Bork AM, Pavão OF, Nogueira-Martins LA, Ferraz MB.
Stressors in ICU: perception of the patient, relatives and health care team.
Intensive Care Med. 1999;25:1421–6.•  We accept pre-submission inquiries 
•  Our selector tool helps you to find the most relevant journal
•  We provide round the clock customer support 
•  Convenient online submission
•  Thorough peer review
•  Inclusion in PubMed and all major indexing services 
•  Maximum visibility for your research
Submit your manuscript at
www.biomedcentral.com/submit
Submit your next manuscript to BioMed Central 
and we will help you at every step:
